Apitope Overview

  • Year Founded
  • 2002

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 1

Employees

  • Latest Deal Type
  • M&A

  • Investors
  • 1

Apitope General Information

Description

Developer of antigen-specific therapeutic peptides designed to develop novel therapeutics that directly target the underlying cause of allergy and autoimmune disease. The company's peptides are focused on the treatment of allergy and autoimmune diseases including multiple sclerosis, Graves' disease, and Uveitis, enabling patients to enjoy a normal quality of life without the risk of secondary infection and further complications.

Contact Information

Website
www.apitope.com
Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Corporate Office
  • Agoralaan
  • Building A-bis
  • 3590 Diepenbeek
  • Belgium
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Acquirer
Corporate Office
  • Agoralaan
  • Building A-bis
  • 3590 Diepenbeek
  • Belgium

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Apitope Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Merger/Acquisition 21-Sep-2021 Completed Clinical Trials - Phase 2
6. Secondary Transaction - Private 01-Mar-2021 Completed Clinical Trials - Phase 2
5. Later Stage VC (Series B) 29-Sep-2015 Completed Pre-Clinical Trials
4. Grant 08-Jan-2014 Completed Pre-Clinical Trials
3. Grant 21-Dec-2012 Completed Pre-Clinical Trials
2. Later Stage VC (Series A) 09-Dec-2009 $14.9M $14.9M Completed Pre-Clinical Trials
1. University Spin-Out 01-Jan-2002 Completed Startup
To view Apitope’s complete valuation and funding history, request access »

Apitope Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Category B
Category B
To view Apitope’s complete cap table history, request access »

Apitope Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of antigen-specific therapeutic peptides designed to develop novel therapeutics that directly target the under
Drug Discovery
Diepenbeek, Belgium
1 As of 2021

Cambridge, MA

Basel, Switzerland
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Apitope Competitors (75)

One of Apitope’s 75 competitors is AnTolRx, a Formerly VC-backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
AnTolRx Formerly VC-backed Cambridge, MA
Baliopharm Venture Capital-Backed Basel, Switzerland
CuraVac Formerly Accelerator/Incubator backed Rixensart, Belgium
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
Agomab Therapeutics Formerly VC-backed Antwerp, Belgium
You’re viewing 5 of 75 competitors. Get the full list »

Apitope Patents

Apitope Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20230203126-A1 A composition comprising s-arrestin peptides Pending 23-Dec-2019
WO-2021130653-A1 A composition comprising s-arrestin peptides Inactive 23-Dec-2019
GB-201919222-D0 Composition Inactive 23-Dec-2019
GB-201909774-D0 Method Inactive 08-Jul-2019
US-20220260587-A1 Method Inactive 08-Jul-2019 G01N33/6878
To view Apitope’s complete patent history, request access »

Apitope Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Apitope Former Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
Arix Capital Management Asset Manager Minority
European Commission Government
LRM Venture Capital Minority
National Multiple Sclerosis Society (NMSS) Not-For-Profit Venture Capital Minority
PMV (Belgium) Asset Manager Minority
You’re viewing 5 of 10 investors. Get the full list »

Apitope FAQs

  • When was Apitope founded?

    Apitope was founded in 2002.

  • Where is Apitope headquartered?

    Apitope is headquartered in Diepenbeek, Belgium.

  • What is the size of Apitope?

    Apitope has 1 total employees.

  • What industry is Apitope in?

    Apitope’s primary industry is Drug Discovery.

  • Is Apitope a private or public company?

    Apitope is a Private company.

  • What is Apitope’s current revenue?

    The current revenue for Apitope is .

  • How much funding has Apitope raised over time?

    Apitope has raised $28.4M.

  • Who are Apitope’s investors?

    Arix Capital Management, European Commission, LRM, National Multiple Sclerosis Society (NMSS), and PMV (Belgium) are 5 of 10 investors who have invested in Apitope.

  • Who are Apitope’s competitors?

    AnTolRx, Baliopharm, CuraVac, Inovio Pharmaceuticals, and Agomab Therapeutics are some of the 75 competitors of Apitope.

  • When was Apitope acquired?

    Apitope was acquired on 21-Sep-2021.

  • Who acquired Apitope?

    Apitope was acquired by Worg.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process